US Patent

US12251384 — Particulate composition

Formulation · Assigned to Verona Pharma Ltd · Expires 2044-06-25 · 18y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a particulate composition containing ensifentrine, a specific impurity, and another compound, used in liquid pharmaceutical compositions.

USPTO Abstract

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

Drugs covered by this patent

Patent Metadata

Patent number
US12251384
Jurisdiction
US
Classification
Formulation
Expires
2044-06-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Verona Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.